Skip to main content
HCPCS J3375 · Level II · Part B drug

J3375: vancomycin hydrochloride (Tyzavan), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J3375

Billing unit
10 MG
Inj, vanco (tyzavan) 10mg
ASP payment limit
$0.143
October 2026; +0.7% vs July 2026
Practitioner MUE
600
MAI 3
OPPS status
SI N
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J3375 is the Level II code for Injection, vancomycin hydrochloride (tyzavan), not therapeutically equivalent to j3373, 10 mg, billed per 10 MG. The Medicare Part B ASP payment limit for October 2026 is $0.143 per billing unit, up 0.7% from July 2026. The practitioner MUE allows up to 600 units per date of service (MAI 3), so a full 600-unit day is $85.80 at the current limit. Under OPPS it carries status indicator N. The 10 mg billing unit means doses are reported in multiples of ten milligrams, with any remainder rounded per contractor policy; mismatched units against the NDC quantity trigger MUE and NDC-unit edits. Other HCPCS codes whose descriptor names vancomycin: J3374 (the Mylan product (manufacturer named in its CMS descriptor)); J3376 (the Hikma product (manufacturer named in its CMS descriptor)); J3373 (the code whose CMS descriptor names no specific product). The ASP crosswalk maps 14 NDCs to it, sold as Tyzavan, Vancomycin HCl by Hikma Pharmaceuticals USA Inc., Xellia Pharmaceuticals USA, LLC. No current Billing and Coding Article lists J3375, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J3375 at $0.143 per 10 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $0.142 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J3375
QuarterPayment limitPerCoinsurance
October 2026$0.14310 MG20%
July 2026$0.14210 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 14 NDCs from 2 labelers to J3375. Report the NDC in the claim's drug segment and bill the number of J3375 units that equals the quantity administered divided by 10 MG; the last column gives units per full package.

NDCs that crosswalk to J3375
NDCDrug nameLabelerPackage sizeBilling units / package
00143-9466-06TyzavanHikma Pharmaceuticals USA Inc.250 × 6750
00143-9467-06TyzavanHikma Pharmaceuticals USA Inc.350 × 61050
00143-9468-12TyzavanHikma Pharmaceuticals USA Inc.150 × 12900
00143-9469-06TyzavanHikma Pharmaceuticals USA Inc.300 × 6900
00143-9470-06TyzavanHikma Pharmaceuticals USA Inc.400 × 61200
00143-9471-12TyzavanHikma Pharmaceuticals USA Inc.100 × 12600
00143-9472-12TyzavanHikma Pharmaceuticals USA Inc.200 × 121200
70594-0041-03Vancomycin HClXellia Pharmaceuticals USA, LLC.100 × 12600
70594-0042-03Vancomycin HClXellia Pharmaceuticals USA, LLC.200 × 121200
70594-0043-02Vancomycin HClXellia Pharmaceuticals USA, LLC.200 × 6900
70594-0044-02Vancomycin HClXellia Pharmaceuticals USA, LLC.400 × 61200
70594-0056-03Vancomycin HClXellia Pharmaceuticals USA, LLC.150 × 12900
70594-0057-02Vancomycin HClXellia Pharmaceuticals USA, LLC.250 × 6750
70594-0058-02Vancomycin HClXellia Pharmaceuticals USA, LLC.350 × 61050

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J3375. For practitioners the limit is 600 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J3375 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services6003 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital6003 Date of Service Edit: ClinicalPrescribing Information
DME supplier6003 Date of Service Edit: ClinicalPrescribing Information

MUE for J3375 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J3375 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J3375 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J3375 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J3375 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J3375 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.

Common denials for J3375 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J3375

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J3375

What does HCPCS code J3375 describe?

J3375 is defined by CMS as "Injection, vancomycin hydrochloride (tyzavan), not therapeutically equivalent to j3373, 10 mg". Each billing unit represents 10 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J3375 a CPT code?

No. J3375 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as vancomycin hydrochloride (Tyzavan); CPT codes are five-character codes maintained by the AMA. On a Part B claim J3375 reports the drug itself in 10 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J3375 in October 2026?

The ASP-based payment limit is $0.143 per 10 MG, with 20% beneficiary coinsurance. The July 2026 limit was $0.142. Commercial payers use their own fee schedules.

How many units of J3375 can be billed per day?

The practitioner Medically Unlikely Edit is 600 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J3375?

The October 2026 ASP crosswalk lists 14 NDCs from 2 labelers: Tyzavan (Hikma Pharmaceuticals USA Inc.); Vancomycin HCl (Xellia Pharmaceuticals USA, LLC.). For example NDC 00143-9466-06 (package size 250) equals 750 billing units of J3375.

Does J3375 have NCCI bundling edits?

No active practitioner PTP pairs list J3375 as a column-1 or column-2 code in the v323r0 release.

J3375 vs J3374: what is the difference?

Both are HCPCS Level II codes whose descriptor names vancomycin hydrochloride. What sets J3374 apart: the Mylan product (manufacturer named in its CMS descriptor). J3375 is billed per 10 mg, limit $0.143, MUE 600; J3374 is billed per 10 mg, limit $0.091, MUE 600. Report the code whose descriptor matches the product and setting in the record.

J3375 vs J3376: what is the difference?

Both are HCPCS Level II codes whose descriptor names vancomycin. What sets J3376 apart: the Hikma product (manufacturer named in its CMS descriptor). J3375 is billed per 10 mg, limit $0.143, MUE 600; J3376 is billed per 10 mg, limit $0.016, MUE 600. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.